Skip to main content

FDA Approvals

FDA Approvals, In the News, Select Drug Profiles

Tibsovo Now FDA Approved as First-Line Treatment for AML with IDH1 Mutation

FDA Approvals, In the News, Select Drug Profiles

FDA Approves Pembrolizumab plus Axitinib for Advanced Renal-Cell Carcinoma

FDA Approvals, In the News, Select Drug Profiles

April 16, 2019 – FDA Approvals, News & Updates

Breast Cancer, FDA Approvals, In the News, Select Drug Profiles

FDA Approves First Hormonal-Based Therapy for Men with Advanced or Metastatic Breast Cancer

Breast Cancer, FDA Approvals, In the News, Select Drug Profiles

Proposed Landmark Policy Changes to Modernize Mammography and Raise Breast Density Awareness

FDA Approvals, In the News, Lung Cancer, Select Drug Profiles

FDA Approves Tecentriq plus Chemotherapy for First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer

FDA Approvals, In the News, Select Drug Profiles

FDA Approves Tecentriq plus Abraxane—First Immunotherapy for PD-L1– Positive Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

FDA Approvals, In the News, Select Drug Profiles

March 08, 2019 - FDA Approvals, News & Updates

FDA Approvals, In the News, Select Drug Profiles

FDA Approves Pembrolizumab for Treatment of Advanced Melanoma

FDA Approvals, In the News, Select Drug Profiles

FDA Approves Split-Dosing Regimen for Daratumumab in Patients with Multiple Myeloma

10
11
12
13
14
15
16

Page 13 of 18
Results 121 - 130 of 180